CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC)

[1] Inamura K(2017)Renal cell tumors: understanding their molecular pathological epidemiology and the 2016 WHO classification Int J MolSci 18 2195-511

[2] Owens B(2016)Kidney cancer Nature 537 S97-13

[3] Posadas EM(2017)Targeted therapies for renal cell carcinoma Nat Rev Nephrol 13 496-287

[4] Limvorasak S(2015)Tumor microenvironment: sanctuary of the devil Cancer Lett 368 7-1132

[5] Figlin RA(2020)Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies Signal Transd Target Ther 5 99-264

[6] Hui L(2019)Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab Sci Rep 9 14039-2350

[7] Chen Y(2016)Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy Nat Rev Cancer 16 275-37

[8] Cervantes-Villagrana RD(2012)Immunology beats cancer: a blueprint for successful translation Nat Immunol 13 1129-667

[9] Albores-Garcia D(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-115

[10] Cervantes-Villagrana AR(2018)Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC N Engl J Med 379 2342-1725

[1] Inamura K(2017)Renal cell tumors: understanding their molecular pathological epidemiology and the 2016 WHO classification Int J MolSci 18 2195-511

[2] Owens B(2016)Kidney cancer Nature 537 S97-13

[3] Posadas EM(2017)Targeted therapies for renal cell carcinoma Nat Rev Nephrol 13 496-287

[4] Limvorasak S(2015)Tumor microenvironment: sanctuary of the devil Cancer Lett 368 7-1132

[5] Figlin RA(2020)Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies Signal Transd Target Ther 5 99-264

[6] Hui L(2019)Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab Sci Rep 9 14039-2350

[7] Chen Y(2016)Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy Nat Rev Cancer 16 275-37

[8] Cervantes-Villagrana RD(2012)Immunology beats cancer: a blueprint for successful translation Nat Immunol 13 1129-667

[9] Albores-Garcia D(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-115

[10] Cervantes-Villagrana AR(2018)Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC N Engl J Med 379 2342-1725